Advertisement

Topics

Search Results for "BIAL Pharmaceuticals"

07:46 EDT 17th August 2017 | BioPortfolio

Matching Channels

Massachusetts

Located in the north-east corner of the USA, Massachusetts, has the third highest GDP of any state in America and is also a hotspot for the biotechnology industry. In addition to the globally renown...

The Top 100 Drugs

The pharmaceutical industry is massive, both in range of products and in financial values. These are the top 200 drugs (ranked in descending order according to total sales in 20010, $), and the co...

Datamonitor - aims to help its clients operating in the pharmaceuticals, healthcare and biotechnology fields, offering world-leading products and services to meet the challenges of this rapidly evolving marketplace

The Datamonitor Group aims to help its clients operating in the pharmaceuticals, healthcare and biotechnology fields, offering world-leading products and services to meet the challenges of this rapi...

Michigan

Surrounded by the Great Lakes in the north east of the US, Michigan hosts many high profile biotechnology companies and has become an industry hotbed. In 1993 MichBio was formed, as an industry tr...

Covidien

Covidien is the 9th largest global medical device company with annual sales in 2010 of almost $8 billion. Covidien was originally Tyco Healthcare, until June 2007, and has seen year-on-year growth s...

Matching News

Bial and Eisai report positive results from Phase II trial of Zebinix for epilepsy

Bial and Eisai have reported a positive outcome from a Phase II clinical trial (Study 208) of Zebinix (eslicarbazepine acetate) in children with focal-onset epilepsy.

Bial and Eisai receive positive opinion for Zebinix to treat focal onset epilepsy

Bial and Eisai have announced the receipt of a positive opinion for Zebinix (eslicarbazepine acetate) from the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) to treat...

Team describes off-target effects of Bial's FAAH inhibitor

EC approves label expansion for Bial-Portela's epilepsy drug Zebinix

Bial launches video campaign for World Parkinson’s Day

Aims to challenge negative portrayals of people with the disease

NeuroBreak: Deadly BIAL Drug Hits Many Targets; Spinraza OK'd in the EU

(MedPage Today) -- News and commentary from the world of neurology and neuroscience

Monotherapy approved to treat epilepsy in Europe

Portugal's largest drugmaker Bial and Japanese pharma major Eisai have announced approval from the European…

No harm to brain function from Zebinix/Aptiom, data shows

Portuguese pharma firm BIAL and Japan’s Eisai have announced data from a Phase II study which showed…

Matching PubMed Articles

Progress Confirmed for Pharmaceuticals in 2016.

n/a.

Temporal and spatial behavior of pharmaceuticals in Narragansett Bay, Rhode Island, United States.

The behavior and fate of pharmaceutical ingredients in coastal marine ecosystems is not well understood. To address this, the spatial and temporal distribution of 15 high volume pharmaceuticals were m...

Announcing the 2017 Pharmaceuticals Travel Award for Young Post-Doctoral Researchers.

Last year, for the first time in its history, our Journal was able to offer a travel grant of 800 CHF to a young researcher in the field of medicinal chemistry.

Chiral pharmaceuticals: A review on their environmental occurrence and fate processes.

More than 50% of pharmaceuticals in current use are chiral compounds. Enantiomers of the same pharmaceutical have identical physicochemical properties, but may exhibit differences in pharmacokinetics,...

About fundamentals and sermonizers. Author's response to the letter on the article "The BIAL/Biotrial case of death of a human volunteer in the first-in-human study of BIA 10-2474: Are we missing the fundamentals?"

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement